A 61-Year-Old Man With Stage 4 Hepatocellular Carcinoma - Episode 2
Pierre Gholam, MD: Those who have a diagnosis of metastatic HCC [hepatocellular carcinoma] from the get-go used to have a dismal prognosis not longer than a decade ago. In fact, we had very limited treatments that would enable these patients to pursue any type of meaningful treatment that would extend life or improve it with systemic therapy and certainly with locoregional therapy.
We have come a long way, as we will discuss in the questions in subsequent intervals of this discussion, in that we have improved dramatically our ability to treat these patients with systemic therapy. We now have multiple lines of therapy that we can offer these patients.
Realistically, with 2 lines of therapy we have multiple examples that can tell us that a patient like this—assuming maintenance of good liver function and a reasonably good performance status—might be able to achieve a significant survival benefit, assuming they respond to first-line and ultimately second-line therapy. In fairness, not every patient with metastatic HCC at this point would realistically expect a 2-plus-year survival. Although I have seen that many times, I think the take-away message here is that treatment options are available in terms of systemic therapy and can help patients live longer. We now know from recent evidence that we can reduce the decrement in quality of life that can incur what patients have in cancer and experiencing a burden of adverse effects.
Transcript edited for clarity.
Case: A 61-Year-Old Man with Stage 4 Hepatocellular Carcinoma
Treatment and Follow-Up